-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Guardant Health, Raises Price Target to $225

Benzinga·09/09/2026 17:51:18
Listen to the news
UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.